Monashee Investment Management LLC Increases Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Monashee Investment Management LLC increased its stake in Structure Therapeutics Inc. by 121.9% during the first quarter, owning a total of 292,862 shares valued at approximately $5 million.
• Institutional investors and hedge funds hold 91.78% of the stock, indicating strong institutional interest in Structure Therapeutics.
• Analysts have a consensus Buy rating on the stock with an average target price of $75.71, reflecting anticipated growth potential.

Monashee Investment Management LLC lifted its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 121.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 292,862 shares of the company's stock after acquiring an additional 160,862 shares during the period. Structure Therapeutics accounts for approximately 0.6% of Monashee Investment Management LLC's portfolio, making the stock its 25th biggest holding. Monashee Investment Management LLC owned 0.51% of Structure Therapeutics worth $5,069,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in GPCR. LPL Financial LLC lifted its stake in shares of Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after purchasing an additional 646 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Structure Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 45,705 shares of the company's stock valued at $1,240,000 after buying an additional 480 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Structure Therapeutics by 202.5% during the 4th quarter. Wells Fargo & Company MN now owns 10,103 shares of the company's stock valued at $274,000 after buying an additional 6,763 shares during the period. Envestnet Asset Management Inc. raised its holdings in shares of Structure Therapeutics by 12.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock valued at $201,000 after buying an additional 843 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Structure Therapeutics by 4.1% during the 4th quarter. Invesco Ltd. now owns 371,767 shares of the company's stock valued at $10,082,000 after buying an additional 14,559 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. HC Wainwright dropped their target price on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. JMP Securities dropped their target price on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Guggenheim dropped their target price on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, Citigroup assumed coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $75.71.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $18.57 on Thursday. The company has a 50 day moving average price of $19.34 and a 200-day moving average price of $21.29. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $13.22 and a fifty-two week high of $45.37. The stock has a market capitalization of $1.07 billion, a PE ratio of -17.69 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). Equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.